Serum Fibroblast Growth Factor 21 as a Novel Biomarker in Prediction of Coronary Artery Disease Severity
Journal Title: Journal of Advances in Medicine and Medical Research - Year 2016, Vol 18, Issue 9
Abstract
Aims: To evaluate serum FGF-21 concentrations in coronary heart disease patients (CHD) whether or not associated with diabetes and/or hypertension. It also investigated the possible association between serum FGF21 and the coronary angiographic findings in terms of number of coronary vessels affected. Study Design: Cross-sectional observational comparative study. Place and Duration of Study: Coronary angiography unit at the Critical Care Department with Biochemistry Department, Kasr Al Aini Medical Hospitals, from January 2013 to March 2014. Methods: Seventy patients (47 Males and 23 females) were classified after coronary angiography into: Sub-group (A): Coronary Artery Disease patients without DM or hypertension; Sub-group (B): Coronary Artery Disease patients with DM and/or hypertension; Sub-group (C): Patients with normal angiography but suffering from DM and/ or hypertension. Twelve healthy individuals were also included in the present study as a control group. Body Mass Index (BMI) were matched for all groups, systolic and diastolic blood pressure (SBP&DBP) and fasting serum levels of FGF21, glucose, insulin and lipid profile were estimated. Results: A significant increase in the levels of FGF-21 was detected in CHD patients compared to control group (325.8 ± 129.2 Vs 202.2 ± 65.8, P =.002) and significant increase was also found in those with multi-vessel disease affection compared to those with one-vessel affection group (392.1 ± 140.4 Vs 250.7 ± 83.8, P =.007), There was a highly significant positive correlation between serum levels of FGF-21 and each of BMI (r= .7, P > .001), SBP (r= .63, P > .001), and DBP (r= .67, P > .001). ROC curve analysis indicated that the optimum cut off value for plasma FGF 21 level in patients with CHD versus control was 236 pg/ml which gives 68.33% sensitivity and 75% specificity. Conclusion: Circulating FGF21 level could be a biomarker for CHD and may be used for assessment of severity of CHD.
Authors and Affiliations
Mervat M. Khalaf, Salwa Fayez, Taha Azouz
Keywords
Related Articles
- EP ID EP340953
- DOI 10.9734/BJMMR/2016/29581
- Views 39
- Downloads 0
Echocardiographic Features of Patients with Stroke in Port Harcourt, Nigeria
Stroke is a major challenge to physicians worldwide, with a high incidence, mortality, disability rates and costs. Systemic hypertension (SH) is the most dominant risk factor for the development of stroke. It results in...
Hypericum perforatum L. as Adjuvant to Opioid Analgesia in an Animal Model of Migraine
Aims: Despite their high analgesic efficacy, opioids can provide only partial pain relief during a migraine attack and their tolerability profile is unsatisfactory. The aim of the present study was to investigate the pot...
Lipoprotein-associated Phospholipase A2, Lp-PLA2, and Age, are Predictors for Future Cardiovascular Events in Acute Coronary Syndrome Patients
Aims: We investigated whether Lp-PLA2 activity of blood samples collected 24 h after hospital admission could serve as a predictor of future cardiovascular events in Vietnamese patients with acute coronary syndrome (ACS)...
Serum and Salivary Cortisol Levels in Diabetics Attending University of Calabar Teaching Hospital, Calabar, Nigeria
Aims: To investigate if salivary cortisol can be used as an alternative to serum cortisol in the management of diabetes mellitus. Study Design: The design of the study was cross sectional. Place and Duration of Study:...
Biomass Fuel Use and Risk of Cataract: Systematic Review and Meta-Analysis
Aims: There is an increasing recognition of the putative association between the use of biomass fuels and the risk of cataracts. However, the exact strength of this association is currently unknown. Our aim was to synthe...